CellCarta
Christopher Ung is an accomplished business executive with extensive experience in the biotechnology and oncology sectors. Currently serving as Chief Business Officer at CellCarta since January 2015, Ung has also contributed as an Advisory Board Member for STC Biologics, a biotechnology firm specializing in biologic drug development. Previously, positions included Chief Business Officer at HistoGeneX, COO and Vice President of Business Development at Ligacept, and President & COO at Biomarker Laboratory, among others. Ung's career includes significant roles at Quintiles Transnational and Dako, where leadership in oncology development and commercialization of companion diagnostics was demonstrated. Ung holds an MBA in General Management from UCLA and an MSc in Chemistry from the University of California, Berkeley.
This person is not in any offices
CellCarta
CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development.With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integratedImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.